Smith Chas P & Associates PA Cpas Cuts Position in Kenvue Inc. (NYSE:KVUE)

Smith Chas P & Associates PA Cpas cut its stake in Kenvue Inc. (NYSE:KVUE) by 13.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,232 shares of the company’s stock after selling 4,527 shares during the period. Smith Chas P & Associates PA Cpas’ holdings in Kenvue were worth $603,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Anderson Hoagland & Co. acquired a new position in Kenvue during the fourth quarter worth about $1,656,000. Juncture Wealth Strategies LLC raised its position in shares of Kenvue by 60.5% during the 4th quarter. Juncture Wealth Strategies LLC now owns 16,713 shares of the company’s stock worth $357,000 after purchasing an additional 6,302 shares during the last quarter. GSB Wealth Management LLC lifted its stake in Kenvue by 0.9% in the 4th quarter. GSB Wealth Management LLC now owns 149,322 shares of the company’s stock valued at $3,188,000 after buying an additional 1,323 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in Kenvue during the 4th quarter valued at $29,000. Finally, Dynamic Advisor Solutions LLC increased its position in Kenvue by 7.9% during the fourth quarter. Dynamic Advisor Solutions LLC now owns 63,497 shares of the company’s stock worth $1,356,000 after buying an additional 4,661 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Up 0.2 %

Kenvue stock opened at $20.79 on Friday. The firm has a 50-day moving average price of $22.14 and a two-hundred day moving average price of $21.78. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The firm has a market capitalization of $39.85 billion, a price-to-earnings ratio of 37.79, a PEG ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.31 EPS. Sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.95%. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several research analyst reports. JPMorgan Chase & Co. upped their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Bank of America increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Barclays reduced their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average target price of $23.08.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.